NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Alembic Pharmaceuticals, Krishna Institute of Medical Sciences, and Latent View Analytics remained in focus after ICICI Securities reviewed their June-quarter earnings, raising target prices for Alembic Pharma and KIMS while downgrading Latent View Analytics due to concerns over near-term revenue growth and margin pressures.
Among the three, Alembic Pharma delivered one of the strongest performances. The company reported a 26% YoY rise in revenue, driven by a sharp recovery in its US business, where sales surged nearly 49% amid new product launches and the exclusive launch of Bosutinib.
ALSO READ: Kalyan Jewellers Shines After Strong Q1; ICICI Securities Raises Target Price — Check Upside
Encouraged by the strong execution, management raised its FY27 US growth guidance, prompting ICICI Securities to maintain its 'Add' rating and increase its target price to Rs 875 from Rs 850.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
